

ENTECAVIR MYLAN

1. Product Name

Entecavir Mylan, 0.5 mg and 1 mg, film-coated tablets.

2. Qualitative and Quantitative Composition

Each film-coated tablet contains entecavir monohydrate equivalent to 0.5 mg or 1 mg of entecavir (anhydrous).

Excipient with known effect: Contains sugars as lactose.

For the full list of excipients, see section 6.1.

3. Pharmaceutical Form

Entecavir Mylan 0.5 mg: white, film-coated, round, biconvex, beveled edge tablet debossed with 'M' on one side of the tablet and 'EV1' on the other side.

Entecavir Mylan 1 mg: white, film-coated, round, biconvex, beveled edge tablet debossed with 'M' on one side of the tablet and 'EV2' on the other side.

4. Clinical Particulars

4.1 *Therapeutic indications*

Entecavir Mylan is indicated for the treatment of chronic HBV infection in adults with evidence of active liver inflammation.

4.2 *Dose and method of administration*

Dose

The recommended oral dose of Entecavir Mylan in adults and adolescents older than 16 years is 0.5 mg once daily. For lamivudine-refractory patients [patients with evidence of viremia while on therapy with lamivudine or the presence of LVDR (YMDD) mutations], the recommended dose is 1 mg once daily.

Duration of Therapy

The optimal duration of treatment with entecavir for patients with chronic hepatitis B infection and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.

Special populations

Renal impairment

In patients with renal impairment, the apparent oral clearance of entecavir decreased as creatinine clearance decreased (see section 5.2). Dosage adjustment is recommended for patients with creatinine clearance <50 mL/min, including patients on haemodialysis or CAPD, as shown in Table 1.

Table 1: Recommended dosage of entecavir in patients with renal impairment, schedule based method

Creatinine Clearance (mL/min)	Usual Dose (0.5 mg)	Lamivudine Refractory (1 mg)
≥50	0.5 mg once daily	1 mg once daily
30 to <50	0.5 mg every 48 hours	1.0 mg every 48 hours
10 to <30	0.5 mg every 72 hours	1.0 mg every 72 hours
<10	0.5 mg every 5 to 7 days	1.0 mg every 5 to 7 days
Hemodialysis or CAPD*	0.5 mg every 5 to 7 days	1.0 mg every 5 to 7 days

*On haemodialysis days administer after haemodialysis.

Hepatic impairment

No dosage adjustment is necessary for patients with hepatic impairment.

Method of administration

Entecavir should be administered on an empty stomach (at least 2 hours after a meal and at least 2 hours before the next meal).

4.3 Contraindications

Entecavir Mylan is contraindicated in patients with previously demonstrated hypersensitivity to entecavir or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Co-infection with HIV

Entecavir has not been evaluated in HIV/HBV co-infected patients not simultaneously receiving HIV treatment. Therapy with entecavir is not recommended in HIV/HBV co-infected patients not receiving highly active antiretroviral therapy. Limited clinical experience suggests that there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus infection in patients with HIV infection that is not being treated.

Lactic acidosis

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals.

Exacerbations of hepatitis after discontinuation of treatment

Acute exacerbation of hepatitis has been reported in patients who have discontinued hepatitis B therapy, including therapy with entecavir (see section 4.8). The majority of post-treatment exacerbations appear to be self-limited. However, severe exacerbations, including fatalities, may occur. The causal relationship of these events to discontinuation of therapy is unknown. Hepatic

function should be monitored at repeated intervals after discontinuation. If appropriate, resumption of hepatitis B therapy may be warranted.

Patients with renal impairment

Dosage adjustment of entecavir is recommended for patients with renal impairment (see section 5.2).

Liver transplant recipients

Limited data are available on the safety and efficacy of entecavir in liver transplant recipients. In a single-arm, open label study, patients who had HBV DNA less than 172 IU/mL at the time of transplant were treated with entecavir 1 mg once daily post-transplant. On treatment, 15 subjects (23%) had liver-related adverse events of interest: 14 subjects had ascites (22%) and 1 subject each had bacterial peritonitis, hepatic encephalopathy, and recurrent HCC. In 12 of the 15 subjects, all liver-related events occurred during the first 30 days post-transplant and were considered post-operative complications. During the first 30 days post-transplant, 18 of 65 treated subjects (28%) or 8 of 61 evaluable subjects (13%) had episodes of acute liver rejection with 1 subject who required re-transplantation. None of the 61 evaluable patients had virologic recurrence. The frequency and nature of adverse events and acute liver rejection in this study were consistent with those expected in patients who have received a liver transplant and the known safety profile of entecavir (see section 5.1).

Renal function should be carefully evaluated before and during entecavir therapy in liver transplant recipients receiving immunosuppressant that may affect renal function such as cyclosporine or tacrolimus (see sections 4.2 and 5.2).

Decompensated liver disease

A study of entecavir at a dose of 1 mg once daily has been conducted in patients with decompensated liver disease (see sections 4.8 and 5.1).

Co-infection with hepatitis C or D

There are no data on the efficacy of entecavir in patients co-infected with hepatitis C or D.

Lactose

This medicinal product contains 62.5 mg of lactose in each 0.5 mg daily dose and 125 mg of lactose in each 1 mg daily dose. Entecavir tablets should be used with caution in patients with lactose intolerance.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency of glucose-galactose malabsorption should not take this medicine.

Patient information

A Consumer Medicine Information Leaflet for entecavir is available for patient information.

Patients should remain under the care of a physician while taking entecavir. They should discuss any new symptoms or concurrent medications with their physician.

Patients should be advised to take entecavir on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).

Patients should be informed that deterioration of liver disease may occur in some cases if treatment is discontinued, and that they should discuss any change in regimen with their physician.

Patients should be advised that treatment with entecavir has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination (see section 4.6).

Special populations

Paediatric

Safety and effectiveness of entecavir in paediatric patients below the age of 16 years have not been established.

Elderly

Clinical studies of entecavir did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Entecavir is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see section 4.2).

4.5 Interaction with other medicines and other forms of interaction

Medicinal products

Since entecavir is predominantly eliminated by the kidney (see section 5.2), co-administration with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of either medicinal product. Co-administration of entecavir with either lamivudine, adefovir dipivoxil or tenofovir disoproxil fumarate resulted in no significant drug interactions. The effects of co-administration of entecavir with other medicinal products that are excreted renally or affect renal function have not been evaluated. Patients should be monitored closely for adverse events when entecavir is co-administered with such medicinal products.

Food

Administration of entecavir with food decreased absorption. (See sections 4.2 and 5.2).

4.6 Fertility, pregnancy and lactation

Pregnancy

Pregnancy Category B3

There are no adequate and well-controlled studies in pregnant women. Entecavir should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

There are no data on the effect of entecavir on transmission of HBV from mother to infant. Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.

When entecavir was orally administered to presumed-pregnant rats, no drug-related changes were observed in either dams or foetuses at maternal exposures approximately 50 times human exposure at 0.5 mg/day (28 times at 1 mg/day). At maternal exposures \geq 318 human exposure at 0.5 mg/day (\geq 180 times at 1 mg/day), embryo-foetal toxicity (resorptions) and maternal toxicity were observed, and at exposure 5498 times human exposure at 0.5 mg/day (3100 times at 1 mg/day), lower foetal body weights, tail and vertebral malformations, reduced ossification (vertebrae, sternbrae, and phalanges), and extra lumbar vertebrae and ribs were observed. When entecavir was orally administered to presumed-pregnant rabbits, no drug-related developmental changes were noted at systemic exposures up to 377 times that in humans at 0.5 mg/day (212 times at 1 mg/day). At exposure 1566 times human exposure at 0.5 mg/day (883 times at 1 mg/day), embryo-foetal toxicity (resorptions), reduced ossification (hyoid), and an increased incidence of 13th rib were observed. In

an oral study of prenatal and postnatal development in rats, entecavir did not affect offspring at exposures >165 times human exposure at 0.5 mg/day (>94 times at 1 mg/day).

Labour and Delivery

There are no studies in pregnant women and no data on the effect of entecavir on transmission of HBV from mother to infant. Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.

Breast-feeding

Entecavir and/or its conjugate metabolites are excreted in the milk of rats. It is not known whether it is excreted in human milk. Mothers should be instructed not to breast-feed if they are taking entecavir.

Fertility

For pre-clinical fertility data refer to section 5.3.

4.7 Effects on ability to drive and use machines

Entecavir Mylan may cause common side effects such as dizziness, fatigue, and somnolence, which may impair the ability to drive and use machineries.

4.8 Undesirable effects

Assessment of adverse reactions is based on four clinical studies in which 1720 patients with chronic HBV infection received double-blind treatment with entecavir 0.5 mg/day (n = 679), entecavir 1 mg/day (n = 183), or lamivudine (n = 858) for up to 107 weeks. The safety profiles of entecavir and lamivudine were comparable in these studies. Among entecavir-treated patients, the most common adverse events of any severity with at least a possible relation to entecavir were headache (9%), fatigue (6%), dizziness (4%) and nausea (3%).

In these clinical studies, the 594 entecavir-treated patients who received blinded therapy for more than 52 weeks reported adverse reactions similar in nature and severity to those reported during the first 52 weeks of treatment.

Clinical events

Selected clinical adverse events of moderate-severe intensity and considered at least possibly related to treatment occurring during therapy in four clinical studies in which entecavir was compared to lamivudine are presented in Table 2.

Table 2. Selected Clinical Adverse Events^a of moderate-Severe Intensity (Grades 2-4) Reported in Four Entecavir Clinical Trials

Body System/ Adverse Event	Nucloside-Naive ^b		Lamivudine-Refractory ^c	
	entecavir 0.5 mg n=679	Lamivudine 100 mg n=668	entecavir 1 mg n=183	Lamivudine 100 mg n=190
Gastrointestinal				
Diarrhea	<1%	0	1%	0
Dyspepsia	<1%	<1%	1%	0
Nausea	<1%	<1%	<1%	2%
Vomiting	<1%	<1%	<1%	0

General

Fatigue	1%	1%	3%	3%
---------	----	----	----	----

Nervous System

Headache	2%	2%	4%	1%
Dizziness	<1%	<1%	0	1%
Somnolence	<1%	<1%	0	0

Psychiatric

Insomnia	<1%	<1%	0	<1%
----------	-----	-----	---	-----

^a Includes events of possible, probable, certain or unknown relationship to treatment regimen.

^b Studies AI463022 and AI463027.

^c Includes Study AI463206 and the entecavir 1 mg and lamivudine treatment arms of Study AI463014 a Phase 2 multinational, randomized, double-blind study of three doses of entecavir (0.1, 0.5, and 1 mg) once daily versus continued lamivudine 100 mg once daily for up to 52 weeks in patients who experienced recurrent viremia on lamivudine therapy.

Laboratory findings

Table 3 shows laboratory findings from four double-blind, lamivudine-controlled clinical studies in which 679 nucleoside-naïve patients received entecavir 0.5 mg once daily for a median of 53 weeks and 183 lamivudine-refractory patients received entecavir 1 mg for a median of 69 weeks.

Table 3: Selected Laboratory Abnormalities Reported During Treatment in Four Clinical Trials

Test	Nucleoside-Naïve ^a Entecavir 0.5 mg n=679	Lamivudine-Refractory ^b Entecavir 1 mg n=183
ALT >10 X ULN and >2 X baseline	2%	2%
ALT >3 X baseline	5%	4%
ALT >2 X baseline and total bilirubin >2 X ULN and >2 X baseline	<1%	<1%
Albumin <2.5 g/dL	<1%	0
Amylase >3 X baseline	2%	2%
Lipase >3 X baseline	12%	18%
Platelets <50,000/mm ³	<1%	<1%

^a Median duration of therapy was 53 weeks.

^b Median duration of therapy was 69 weeks
ULN=upper limit of normal.

Among entecavir-treated patients in these studies, on-treatment ALT elevations >10 X ULN and >2 X baseline generally resolved with continued treatment. A majority of these exacerbations were associated with a >2 log₁₀/mL reduction in viral load that preceded or coincided with the ALT elevation. Periodic monitoring of hepatic function is recommended during treatment.

Exacerbations of hepatitis after discontinuation of treatment: Acute exacerbations of hepatitis have been reported in patients who have discontinued anti-HBV therapy, including therapy with entecavir. The frequency of exacerbation of hepatitis or ALT flare (defined as ALT >10X ULN and 2X the patient's reference level) during off-treatment follow-up in clinical studies with entecavir is presented in Table 4.

Table 4: Exacerbation of Hepatitis During Off-Treatment Follow-up in Three Clinical Trials

	Patients with ALT Elevations >10 X ULN and > 2 X Reference ^a	
	Entecavir	Lamivudine
Nucleoside-naïve	28/476 (6%)	43/417 (10%)
HBeAg-positive	4/174 (2%)	13/147 (9%)
HBeAg-negative	24/302 (8%)	30/270 (11%)
Lamivudine-refractory	6/52 (12%)	0/16

^a Reference is the minimum of the baseline or last measurement at end of dosing. Median time to off-treatment exacerbation was 23 weeks for entecavir-treated patients and 10 weeks for lamivudine-treated patients.

Patients co-infected with HIV: Patients co-infected with HBV and human immunodeficiency virus (HIV) who experienced recurrence of HBV viremia while receiving a lamivudine-containing highly active antiretroviral regimen were treated with their lamivudine-containing regimen (lamivudine dose, 300 mg/day) and either entecavir 1 mg once daily or placebo. After 24 weeks of double-blind therapy and a mean of 17 weeks of open-label therapy (where all patients received entecavir), the adverse event and laboratory abnormality profiles were similar for the entecavir and placebo treatment groups. Entecavir has not been evaluated in HIV/HBV co-infected patients who are not concurrently receiving effective HIV treatment (see section 4.4).

Patients with decompensated liver disease

Clinical adverse reactions observed through Week 48 in Study AI463048 in which entecavir 1mg once daily was compared with adefovir dipivoxil in patients with chronic hepatitis B infection and decompensated liver disease are listed in table 5.

Causes of death were generally liver-related, as expected in this population. The time to onset of HCC or death (whichever occurred first) was comparable in the two treatment groups.

Table 5. Selected Safety Outcomes in Study AI463048

	Entecavir 1 mg n=102	Adefovir dipivoxil 10 mg n=89
Clinical Adverse Events^a of Moderate-Severe Intensity (grades 2-4) Through Week 48		
Body System/ Adverse Event		
Gastrointestinal Disorders		
Vomiting	<1%	1%
Diarrhea	0	1%
Investigations		
Blood bicarbonate decreased	2%	0
Nervous System Disorders		
Dizziness	2%	0
Headache	0	1%
Renal and Urinary Disorders		
Renal failure	<1%	2%
General Disorders and Administration Site Conditions		
Fatigue	<1%	1%

Discontinuation for Adverse Event (cumulative)	7%	6%
Deaths (cumulative)	23%	33%
HCC (cumulative)	12%	20%

^a Includes events of possible, probable, certain or unknown relationship to treatment regimen.

Laboratory test abnormalities reported through week 48 in study AI463048 are listed in table 6.

Table 6. Selected Laboratory Abnormalities Reported Through Week 48 in Study AI463048

Test	Entecavir 1 mg n=102
ALT >10 X ULN and >2 X baseline	0
ALT >2 X baseline and total bilirubin >2 X ULN and >2 X baseline	1%
Albumin <2.5 g/dL	30%
Lipase >3 X baseline	10%
Platelets <50,000/mm ³	20%

ULN = upper limit of normal

Post-marketing experience

The following events have been identified during post-approval use of entecavir. Because reports are voluntary from a population of unknown size, an estimate of frequency cannot be made.

Immune system disorders: anaphylactoid reaction

Metabolism and nutrition disorders: Lactic acidosis has been reported, often in association with hepatic decompensation, other serious medical conditions, or drug exposures. Patients with decompensated cirrhosis may be at higher risk for lactic acidosis.

Hepatobiliary disorders: increased transaminases

Skin and subcutaneous tissue disorders: alopecia, rash.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://nzphvc.otago.ac.nz/reporting/>

4.9 Overdose

There is limited experience of entecavir overdosage reported in patients. Healthy subjects who received single entecavir doses up to 40 mg or multiple doses up to 20 mg/day for up to 14 days had no increase in or unexpected adverse events. If overdose occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.

Following a single 1 mg dose of entecavir, a 4 hour haemodialysis session removed approximately 13% of the entecavir dose.

For further advice on management of overdose please contact the National Poisons Information Centre (0800 POISON or 0800 764 766).

5. Pharmacological Properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Nucleoside and nucleotide reverse transcriptase inhibitors.

ATC code: J05AF10

Mechanism of action

Entecavir is a guanosine nucleoside analogue with potent and selective activity against HBV polymerase. It is phosphorylated to the active triphosphate (TP) form, which has an intracellular half-life of 15 hours. Intracellular TP levels are directly related to extracellular entecavir concentrations, with no significant accumulation beyond initial plateau levels. By competing with the natural substrate deoxyguanosine TP, entecavir-TP functionally inhibits all 3 functional activities of the viral polymerase: (1) priming of the HBV polymerase, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand HBV DNA. The entecavir-TP K_i value for inhibition of HBV DNA polymerase is 0.0012 μM . Entecavir-TP is a weak inhibitor of cellular DNA polymerases α , β , and ϵ with K_i values of 18 to 40 μM . It did not inhibit mitochondrial γ polymerase ($K_i > 160 \mu\text{M}$) and did not affect the mitochondrial DNA content of human hepatoma cells *in vitro*. Entecavir inhibited HBV DNA synthesis at a concentration of 0.004 μM in human HepG2 cells transfected with wild-type HBV. IC_{50} values for entecavir against lamivudine-resistant HBV ranged from 0.029-0.061 μM .

Clinical efficacy and safety

Resistance *in vitro*

There was reduced susceptibility to entecavir when LVDR substitutions (M204I/V \pm L180M) were present. Entecavir inhibited the replication of LVDR HBV at 8-fold higher concentrations than that for the wild-type virus in cell-based studies. At extracellular concentrations representative of plasma levels achieved with 1 mg dosing, intracellular entecavir-TP would be expected to surpass those needed to inhibit the enzyme activity of lamivudine-resistant HBV polymerases. Recombinant viruses encoding adefovir-resistant substitutions at either rtN236T or rtA181V remained fully susceptible to entecavir.

Lamivudine-resistant strains harbouring rtL180M plus rtM204V in combination with amino acid substitution rtA181C conferred 16- to 122-fold reductions in entecavir phenotypic susceptibility.

Clinical resistance

Genotyping was performed on paired baseline and on-treatment samples from all continuously treated patients with PCR detectable HBV DNA (≥ 300 copies/mL) at Week 48, 96, 144, 192 and 240 or at the end of dosing to identify any novel or known resistance substitutions that emerged during entecavir therapy. Virologic breakthrough ($\geq 1 \log_{10}$ increase above nadir in HBV DNA by PCR) due to resistance to entecavir requires the existence of primary lamivudine resistance substitutions (M204I/V \pm L180M) along with an additional substitution at residues T184, S202, and/or M250 of the polymerase protein.

Nucleoside-naive studies

Patients in nucleoside-naive studies received 0.5 mg entecavir for up to 96 weeks (see section 5.1 Pharmacodynamic properties: Clinical trials). Study participants who failed to achieve the study-defined complete response by Week 96 were offered continued entecavir treatment in a rollover study. Complete response for HBeAg positive was < 0.7 MEq/mL (approximately 7×10^5 copies/mL)

serum HBV DNA and HBeAg loss and, for HBeAg negative, was <0.7 MEq/mL HBV DNA and ALT normalisation.

By week 96, evidence of emerging amino acid substitution rtS202G with rtM204V and rtL180M was detected in the HBV of 2 subjects and 1 of them experienced virologic rebound (≥ 1 log₁₀ increased above nadir). In addition, emerging amino acid substitution at rtM204I/V and rtL180M, rtL80I or rtV173L, which conferred decreased phenotypic susceptibility to entecavir in the absence of rtT184, rtS202 or rtM250 changes, were detected in the HBV of 3 subjects who experienced virologic rebound.

Results in Table 7 reflect use of a 1 mg dose of entecavir for 147 of 149 patients in Year 3 and 121 patients in Year 4, 108 patients in Year 5 and of combination entecavir plus lamivudine therapy (followed by long-term entecavir monotherapy) for a median of 20 weeks for 130 of 149 patients in Year 3 and for 1 week for 1 of 121 patients in Year 4 in the rollover study. Through Week 240 in nucleoside-naïve studies, genotypic evidence of ETVr substitutions at rtT184, rtS202, or rtM250 was identified in 3 patients treated with entecavir, 2 of whom experienced virologic breakthrough (see table). These substitutions were observed only in the presence of LVDr substitutions (rtM204V and rtL180M).

Table 7. Genotypic Resistance to Week 240, Nucleoside-Naïve Studies

	Year 1	Year 2	Year 3 ^a	Year 4 ^a	Year 5 ^a
Patients treated and monitored for resistance ^b	663	278	149	121	108
Patients in specific year with:					
emerging genotypic entecavir resistance ^c	1	1	1	0	0
genotypic entecavir resistance ^c with virologic breakthrough ^d	1	0	1	0	0
Cumulative probability of:					
emerging genotypic entecavir resistance ^c	0.2%	0.5%	1.2%	1.2%	1.2%
genotypic entecavir resistance ^c with virologic breakthrough ^d	0.2%	0.2%	0.8%	0.8%	0.8%

^a Results reflect use of a 1-mg dose of entecavir for 147 of 149 patients in Year 3 and all patients in Years 4 and 5 and of combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a median of 20 weeks for 130 of 149 patients in Year 3 and for 1 week for 1 of 121 patients in Year 4 in a rollover study.

^b Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through Week 58 (year 1), after Week 58 through Week 102 (year 2), after Week 102 through Week 156 (year 3), after week 156 through week 204 (Year 4), or after week 204 through week 252 (Year 5).

^c Entecavir resistance substitutions at residues rtT184, rtS202, or rtM250. Patients also have lamivudine resistance substitutions (rtM204V and rtL 180M).

^d $\geq \log_{10}$ increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the windowed time point.

Lamivudine-refractory studies

Participants treated with entecavir 1 mg once daily in lamivudine- refractory studies (see section 5.1 Pharmacodynamic properties - Clinical trials) who failed to achieve the study-defined complete response by Week 96 were offered continued entecavir treatment in a rollover study. Participants received 1 mg entecavir once daily for up to an additional 96 weeks. Genotypic analysis of clinical samples from lamivudine-refractory patients identified emerging entecavir resistance substitutions in 11/187 patients in Year 1, 12/146 patients in Year 2, 16/80 patients in Year 3, 6/52 patients in Year 4 and 2/33 patients in Year 5 (see Table 8). Results in Table 8 reflect the use of combination

entecavir plus lamivudine therapy (followed by long-term entecavir monotherapy) for a median of 13 weeks for 48 of 80 patients in Year 3, for a median of 38 weeks for 10 of 52 patients in Year 4 and for 16 weeks for 1 of 33 patients in Year 5 in the rollover study. The presence of entecavir resistance substitutions at baseline in isolates from 10 (5%) of 187 lamivudine-refractory patients indicates that prior lamivudine treatment can select these resistance substitutions and that they can exist at a low frequency before entecavir treatment. Three of the 10 patients experienced virologic breakthrough in the 240 weeks of follow-up.

Table 8: Genotypic Entecavir Resistance through Week 240, Lamivudine Refractory Studies

	Year 1	Year 2	Year3 ^a	Year4 ^a	Year5 ^a
Patients treated and monitored for resistance ^b	187	146	80	52	33
Patients in specific year with:					
emerging genotypic entecavir resistance ^c	11	12	16	6	2
genotypic entecavir resistance ^c with virologic breakthrough ^d	2 ^e	14 ^e	13 ^e	9 ^e	1 ^e
Cumulative probability of:					
emerging genotypic entecavir resistance ^c	6%	15%	36%	47%	51%
genotypic entecavir resistance ^c with virologic breakthrough ^d	1% ^e	11% ^e	27% ^e	41% ^e	44% ^e

^a Results reflect use of a combination entecavir-lamivudine therapy (followed by long-term entecavir therapy) for a median of 13 weeks for 48 of 80 patients in Year 3, a median of 38 weeks for 10 of 52 patients in Year 4, and for 16 weeks for 1 of 33 patients in Year 5 in a rollover study.

^b Includes patients with at least one on-therapy HBV DNA measurement by PCR at or after week 24 through week 58 (Year 1), after week 58 through week 102 (Year 2), after week 102 through week 156 (Year 3), after week 156 through week 204 (Year 4), or after week 204 through week 252 (Year 5).

^c Entecavir resistance substitutions at residues rtT184, rtS202, or rtM250. Patients also have lamivudine resistance substitutions (rtM204V/I ± rtL180M).

^d ≥1 log₁₀ increase above nadir in HBV DNA by PCR, confirmed with successive measurements or at the end of the windowed time point.

^e Entecavir resistance substitutions occurring in any year, virologic breakthrough in specified year.

Integrated analysis of phase 2 and 3 clinical studies

In a post-approval integrated analysis of entecavir resistance data from 17 Phase 2 and 3 clinical studies, an emergent entecavir resistance-associated substitution rtA181C was detected in 5 out of 1461 (0.3%) subjects during treatment with entecavir. This substitution was detected only in the presence of lamivudine-associated substitutions rtL180M plus rtM240V.

Clinical Trials

The safety and efficacy of entecavir were evaluated in four active-controlled trials on five continents. These studies included 1720 patients 16 years of age or older with chronic hepatitis B infection

(serum HBsAg-positive for at least 6 months) accompanied by evidence of viral replication (detectable serum HBV DNA, as measured by the bDNA hybridization or PCR assay). Subjects in Phase 3 Studies AI463022, AI463026, and AI463027 had persistently elevated ALT levels ≥ 1.3 times the upper limit of normal (ULN) and chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis, whereas abnormal ALT was not an entry criterion and liver biopsy was optional in the Phase 2 Study AI463014. The safety and efficacy of entecavir were also evaluated in an active-controlled study of 191 HBV-infected patients with decompensated liver disease and in a study of 68 patients co-infected with HBV and HIV.

Nucleoside-naive patients with compensated liver disease

Outcome at 48 weeks

HBeAg-positive

Study AI463022 was a multinational, randomized, double-blind study of entecavir 0.5 mg once daily versus lamivudine 100 mg once daily for 52 weeks in 709 (of 715 randomized) nucleosidenaive patients with chronic hepatitis B infection and detectable HBeAg. The mean age of patients was 35 years (range 16 to 78), and 75% were male; 57% were Asian, 40% were Caucasian, and 13% had previously received interferon- α treatment. At baseline, patients had a mean Knodell Necroinflammatory Score of 7.8, mean serum HBV DNA level as measured by Roche COBAS Amplicor[®] PCR assay of 9.66 log₁₀ copies/mL, and mean serum ALT level of 143 U/L. Response was assessed at week 52 based on test results obtained at the week 48 visit. 96 percent of patients had a baseline liver biopsy, paired samples were collected for 89% of patients.

HBeAg-negative (anti-HBe positive/HBV DNA positive)

Study AI463027 was a multinational, randomized, double-blind study of entecavir 0.5 mg once daily versus lamivudine 100 mg once daily for 52 weeks in 638 (of 648 randomized) nucleosidenaive patients with HBeAg-negative (HBeAb-positive) chronic hepatitis B infection (presumed to have pre-core or core-promoter mutants). The mean age of patients was 44 years (range 18 to 77), and 76% were male. Thirty-nine percent were Asian and 58% were Caucasian; 13% had previously received interferon- α treatment. At baseline, patients had a mean Knodell Necroinflammatory Score of 7.8, mean serum HBV DNA level as measured by Roche COBAS

Amplicor PCR assay of 7.58 log₁₀ copies/mL, and mean serum ALT level of 141.7 U/L. Ninety-eight percent of patients had a baseline liver biopsy, and 89% had a biopsy at Week 48; paired samples were collected for 88% of patients. Response was assessed at Week 52 based on test results obtained at the Week 48 visit.

In Studies AI463022 and AI463027, entecavir was superior to lamivudine on the primary efficacy endpoint of Histologic Improvement, defined as ≥ 2 -point reduction in Knodell Necroinflammatory Score with no worsening in Knodell Fibrosis Score at Week 48. Histologic Improvement and change in Ishak Fibrosis Score are shown in Table 9. Biochemical, virologic, and serologic outcome measures are shown in Table 10.

Table 9: Histologic Improvement and Change in Ishak Fibrosis Score at Week 48, Nucleoside-Naive Patients in Studies AI463022 and AI463027

	Study AI463022 (HBeAg-Positive)			Study AI463027 (HBeAg-Negative)		
	Entecavir 0.5 mg n=314 ^a	Lami- vudine 100 mg n=314 ^a	Difference Entecavir lamivudine (95% CI) ^b	Entecavir 0.5 mg n=296 ^a	Lami- vudine 100 mg n=287 ^a	Difference Entecavir lamivudine (95% CI) ^b
Histologic Improvement (Knodell Scores)						
Improvement ^c	72%	62%	9.9% ^d (2.6%, 17.2%)	70%	61%	9.6% ^e (2.0%, 17.3%)
No improvement	21%	24%		19%	26%	

Ishak Fibrosis Score^f						
Improvement ^f	39%	35%	3.2% ^g (-4.4%, 10.7%)	36%	38%	-1.8% ^g (-9.7%, 6.0%)
No change	46%	40%		41%	34%	
Worsening ^f	8%	10%		12%	15%	
Inadequate Week 48 biopsy	2%	5%		2%	1%	
Missing Week 48 biopsy	5%	9%		8%	11%	

^a Patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score ≥ 2).

^b In these analyses, missing or inadequate biopsies at Week 48 were classified "no improvement."

^c ≥ 2 -point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.

^d $p < 0.01$.

^e $p < 0.05$.

^f For Ishak Fibrosis Score, improvement = ≥ 1 -point decrease from baseline and worsening = ≥ 1 -point increase from baseline.

^g Not significant.

CI = confidence interval.

Table 10: Biochemical, Virologic, and Serologic Endpoints at Week 48, Nucleoside-Naive Patients in Studies AI463022 and AI463027

	Study AI463022 (HBeAg-Positive)			Study AI463027 (HBeAg-Negative)		
	Entecavir 0.5 mg n=354	Lami- vudine 100 mg n=355	Difference Entecavir lamivudine (95% CI)	Entecavir 0.5 mg n=325	Lami- vudine 100 mg n=313	Difference Entecavir lamivudine (95% CI)
ALT normalization (≤ 1 X ULN) HBV DNA	68%	60%	8.4% ^a (1.3%, 15.4%)	78%	71%	6.9% ^a (0.2%, 13.7%)
Mean change from baseline by PCR ^b (log ₁₀ copies/mL)	-6.86	-5.39	-1.52 ^c (-1.8, -1.3)	-5.04	-4.53	-0.43 ^c (-0.6, -0.3)
Proportion undetectable (< 300 copies/mL) by PCR ^{b,d}	67%	36%	30.3% ^c (23.3%, 37.3%)	90%	72%	18.3% ^c (12.3%, 24.2%)
< 0.7 MEq/mL by bDNA ^f	91%	65%	25.6% ^c (19.8%, 31.4%)	95%	89%	5.9% ^f (1.8%, 10.1%)
Loss of HBeAg	22%	20%		N/A	N/A	
HBeAg seroconversion	21%	18%		N/A	N/A	

^a $p < 0.05$.

^b Roche COBAS Amplicor PCR assay.

^c $p < 0.0001$.

^d At Week 24, HBV DNA < 300 copies/mL by PCR was observed in 42% of entecavir-treated patients and 25% of lamivudine-treated patients ($p < 0.0001$) in Study AI463022 and 74% of entecavir-treated patients and 62% of lamivudine-treated patients ($p = 0.0013$) in Study AI463027.

^e Quantiplex bDNA assay.

^f $p < 0.01$.

CI = confidence interval.

Responses for patients with baseline Knodell Fibrosis Scores of 4 (cirrhosis) were comparable to overall responses on all efficacy outcome measures (all patients had compensated liver disease). Histologic Improvement was independent of baseline HBV DNA or ALT levels.

Covalently closed circular deoxyribonucleic acid (cccDNA) is a stable genomic form of nuclear HBV DNA that serves as a hepatic reservoir of virus, provides the template for HBV transcription, and contributes to viral persistence and relapse. For a subset of patients with paired liver samples in Study AI463022, the mean change from baseline in hepatic cccDNA at Week 48 was $-0.9 \log_{10}$ copies/human genome equivalents (approximately 8-fold reduction) for entecavir-treated patients (n=159) and $-0.7 \log_{10}$ copies/HGEq (approximately 5-fold reduction) for lamivudine-treated patients (n=146). In Study AI463027, the mean change from baseline in hepatic cccDNA at Week 48 was $-0.5 \log_{10}$ copies/HGEq (approximately 3-fold reduction) in each treatment group (n=107 for entecavir-treated patients and n=104 for lamivudine-treated patients).

Lamivudine-Refractory Patients

Outcomes at 48 weeks

Study AI463026 was a multinational, randomized, double-blind study of entecavir in 286 (of 293 randomized) patients with lamivudine-refractory chronic hepatitis B infection. Patients receiving lamivudine at study entry either switched to entecavir 1 mg once daily or continued on lamivudine 100 mg for 52 weeks. The mean age of patients was 39 years (range 16 to 74), and 76% were male; 37% were Asian and 62% were Caucasian. Eighty-five percent had LVD^R mutations at baseline. Patients had a mean Knodell Necroinflammatory Score of 6.5, mean serum HBV DNA level as measured by Roche COBAS Amplicor PCR assay of $9.36 \log_{10}$ copies/mL, and mean serum ALT level of 128 U/L. Response was assessed at Week 52 based on test results obtained at the Week 48 visit. Ninety-eight percent of patients had a baseline liver biopsy, and 88% had a biopsy at Week 48; paired samples were collected for 87% of patients.

In Study AI463026, entecavir was superior to lamivudine on the coprimary endpoints of Histologic Improvement (using the Knodell Score at Week 48) and Composite Endpoint (proportion of patients with HBV DNA <0.7 MEq/mL by bDNA assay and ALT <1.25 ULN at Week 48). These results and change in Ishak Fibrosis Score are shown in Table 11. Table 12 shows biochemical, virologic, and serologic endpoints.

Table 11: Histologic Improvement, Change in Ishak Fibrosis Score, and Composite Endpoint at Week 48, Lamivudine-Refractory Patients in Study AI463026^a

	Entecavir 1 mg n=124 ^a	Lamivudine 100 mg n=116 ^a	Difference Entecavir- lamivudine (97.5% CI)
Histologic Improvement (Knodell Scores)			
Improvement ^b	55%	28%	27.3% ^{c,d} (13.6%, 40.9%)
No improvement	34%	57%	
Ishak Fibrosis Score^e			
Improvement ^e	34%	16%	17.5% ^{c,f} (6.8%, 28.2%) ^g
No change	44%	42%	
Worsening ^e	11%	26%	
Missing Week 48 biopsy	11%	16%	
Complete Endpoint^h	n=141 55%	n=145 4%	50.5% ^d (40.4%, 60.6%)

- ^a Patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score ≥ 2).
- ^b ≥ 2 -point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell Fibrosis Score.
- ^c In this analysis, missing or inadequate biopsies at Week 48 were classified “no improvement.”
- ^d $p < 0.0001$.
- ^e For Ishak Fibrosis Score, improvement = ≥ 1 -point decrease from baseline and worsening = ≥ 1 -point increase from baseline.
- ^f $p < 0.01$.
- ^g 95% confidence interval.
- ^h Composite Endpoint (a coprimary endpoint) was defined as HBV DNA < 0.7 MEq/mL by bDNA assay and serum ALT ($< 1.25 \times$ ULN) at Week 48.
- CI = confidence interval.

Table 12: Biochemical, Virologic, and Serologic Endpoints at Week 48, Lamivudine-Refractory Patients in Study AI463026

	Entecavir 1 mg n=141	Lamivudine 100 mg n=145	Difference Entecavir- lamivudine (95% CI)
ALT normalization ($\leq 1 \times$ ULN)	61%	15%	45.8% ^b (35.9%, 55.8%)
HBV DNA Mean change from baseline by PCR ^b (\log_{10} copies/mL)	-5.11	-0.48	-4.39 ^a (-4.8, -4.0)
Proportion undetectable (< 300 copies/mL) by PCR ^{b,c}	19%	1%	17.8% ^a (11.0%, 24.5%)
< 0.7 MEq/mL by bDNA ^d	66%	6%	60.4% ^a (51.8%, 69.1%)
Loss of HBeAg	10%	3%	
HBeAg seroconversion	8%	3%	

- ^a $p < 0.0001$.
- ^b Roche COBAS Amplicor PCR assay.
- ^c At Week 24, HBV DNA < 300 copies/mL by PCR was observed in 7% of entecavir-treated patients and no lamivudine-treated patients ($p = 0.0011$).
- ^d Quantiplex bDNA assay.
- CI = Confidence interval.

In Study AI463026, responses for patients with baseline Knodell Fibrosis Scores of 4 (cirrhosis) were comparable to overall responses on all efficacy outcome measures (all patients had compensated liver disease). Histologic Improvement was independent of baseline HBV DNA or ALT levels.

For a subset of patients with paired liver samples in Study AI463026, the mean change from baseline in hepatic cccDNA at Week 48 was $-0.6 \log_{10}$ copies/HGEq (approximately 4-fold reduction) for Entecavir-treated patients ($n = 74$) and $0.0 \log_{10}$ copies/HGEq for lamivudine-treated patients ($n = 59$).

Health-related quality of life (HRQoL) was assessed in Study AI463026 using the standardized and validated EQ-5D instrument developed by the EuroQol group. After 48 weeks of therapy, entecavir-treated patients experienced significantly less worsening compared to lamivudine-treated patients in the dimensions of mobility, self care, and pain/discomfort.

Outcomes beyond 48 weeks

The optimal duration of therapy with entecavir is unknown. According to protocol mandated criteria in the Phase 3 clinical trials, participants discontinued entecavir or lamivudine treatment after 52 weeks according to a definition of response based on HBV virologic suppression (< 0.7 mEq/mL by bDNA assay) and either loss of HBeAg in HBeAg-positive participants, or ALT $< 1.25 \times$ ULN in

HBeAg-negative participants at Week 48. Participants who achieved virologic suppression but did not have serologic response (HBeAg-positive) or did not achieve ALT $<1.25 \times$ ULN (HBeAg-negative) continued blinded dosing until 96 weeks or until the response criteria were met. These protocol-specific participant management guidelines are not intended as guidance for clinical practice.

Nucleoside-naïve HBeAg-positive

Among nucleoside-naïve HBeAg-positive participants (Study AI463022), 243/354 (69%) entecavir-treated participants and 164/355 (46%) lamivudine-treated participants continued blinded treatment for up to 96 weeks. Of those continuing blinded treatment in year 2, 180/243 (74%) entecavir-treated participants and 60/164 (37%) lamivudine-treated participants achieved HBV DNA <300 copies/mL by PCR at the end of dosing; 193/243 (79%) entecavir-treated participants achieved ALT $\leq 1 \times$ ULN compared to 112/164 (68%) lamivudine-treated participants. The number of participants with virologic response but not serologic response who achieved a loss of HBeAg at the end of dosing in the second year of blinded treatment was 37/243 (15%) for entecavir and 28/164 (17%) for lamivudine. The proportion who achieved HBeAg seroconversion was 26/243 (11%) for entecavir and 20/164 (12%) for lamivudine.

Post-treatment follow-up: Among nucleoside-naïve HBeAg-positive participants, 111/354 (31%) entecavir-treated participants and 93/355 (26%) lamivudine-treated participants met the definition of response at end of dosing, discontinued study drugs, and were followed off-treatment for up to 24 weeks. In this cohort, 34/111 (31%) entecavir-treated patients and 27/93 (29%) lamivudine-treated patients had HBV DNA <300 copies/mL by PCR at the end of follow-up. At the end of follow-up, 78/111 (70%) of the entecavir group and 59/93 (63%) of the lamivudine group recorded ALT $\leq 1 \times$ ULN.

Nucleoside-naïve HBeAg-negative

Among nucleoside-naïve, HBeAg-negative participants (Study AI463027), 26/325 (8%) entecavir-treated participants and 28/313 (9%) lamivudine-treated participants continued blinded treatment for up to 96 weeks. In the cohorts continuing treatment, 22/26 entecavir-treated and 16/28 lamivudine-treated participants had HBV DNA <300 copies/mL by PCR; 7 entecavir-treated and 6 lamivudine-treated patients had ALT $\leq 1 \times$ ULN at the end of dosing (up to 96 weeks).

Post-treatment follow-up: Among the nucleoside-naïve, HBeAg-negative participants, 286/325 (88%) treated with entecavir and 253/313 (81%) treated with lamivudine met the definition of response at end of dosing, discontinued study drugs and were followed off-treatment for up to 24 weeks. In this cohort, 7/286 (2%) entecavir-treated patients and 10/253 (4%) lamivudine-treated patients had HBV DNA <300 copies/mL by PCR at the end of follow-up. At the end of follow-up 129/286 (45%) in the entecavir group and 85/253 (34%) in the lamivudine group recorded ALT $\leq 1 \times$ ULN.

Liver biopsy results

57 patients from the pivotal nucleoside-naïve studies AI463022 (HBeAg positive) and AI463027 (HBeAg negative) who enrolled in a long-term rollover study were evaluated for long-term liver histology outcomes. All 57 patients had both an evaluable baseline and long-term biopsy with a median duration of entecavir monohydrate therapy of 280 weeks (approximately 6 years).

55 of 57 (96%) of these patients had Histologic Improvement (a ≥ 2 -point decrease in Knodell necroinflammatory score from baseline with no worsening of the Knodell fibrosis score), and 50 of 57 (88%) had a ≥ 1 -point decrease in Ishak fibrosis score. Of the 43 patients with a baseline Ishak fibrosis score of ≥ 2 , 58% had a ≥ 2 point decrease. All (10/10) patients with advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score of 4,5 or 6) had a ≥ 1 point decrease (median decrease from baseline of 1.5 points). At the time of the long-term biopsy, 57 (100%) of patients had HBV DNA < 300 copies/mL and 49 (86%) had serum ALT $\leq 1 \times$ ULN.

Lamivudine-Refractory

Among lamivudine-refractory participants (Study AI463026), 77/141 (55%) in the entecavir-treated group and 3/145 (2%) in the lamivudine-treated group continued blinded treatment for up to 96 weeks. In the entecavir-treated cohort, 31/77 (40%) achieved HBV DNA <300 copies/mL, 62/77 (81%) had ALT ≤ 1 X ULN and 8/77 (10%) demonstrated HBeAg seroconversion at the end of dosing.

Post-treatment follow-up: Of the 22/141 (16%) lamivudine-refractory patients who met response criteria (HBV DNA <0.7 mEq/mL on bDNA assay and loss of HBeAg) while receiving entecavir, 5/22 (23%) had HBV DNA <300 copies/mL by PCR and 12/22 (55%) had ALT ≤1 X ULN at the end of follow-up.

Outcomes of Long-term Follow-up Study

Study AI463080 was a randomized, global, observational, open-label Phase 4 study to assess long-term risks and benefits of entecavir (0.5 mg/day or 1 mg/day) treatment as compared to other standard of care hepatitis B virus nucleos(t)ide analogues (nucs) in subjects with chronic HBV (CHB) infection.

A total of 12,378 patients with CHB were treated with ETV (n=6,216) or other standard of care HBV nucleoside (acid) treatment (non-ETV) (n=6,162). The patients were evaluated at baseline and subsequently twice a year (every 6 months) on clinical outcome events (COEs) for up to 10 years during the study. The principal COEs assessed in the study were overall malignant neoplasms, liver-related HBV disease progression, non-HCC malignant neoplasms, HCC, non-HCC HBV disease progression, and deaths, including liver-related deaths. The study data showed that ETV was not significantly associated with an increased risk of malignant neoplasms compared to use of other standard of care HBV nucs, as assessed by either the composite endpoint of overall malignant neoplasms or the individual endpoint of non-HCC malignant neoplasm. The most commonly reported malignancy was HCC followed by gastrointestinal malignancies with colorectal and gastric cancers representing the majority of the observed tumour types within the gastrointestinal system in both ETV and non-ETV groups. The data also showed that long-term ETV use was not associated with a lower occurrence of HBV disease progression or a lower rate of death overall.

There were significant population changes over the long-term follow-up period and more frequent post-randomisation treatment changes in the non-ETV group were noted. The study was underpowered to demonstrate a difference in the non-HCC malignancy rate because of the overall lower than expected background rate.

The principal COE assessment is shown in Table 13:

Table 13. Principal Analyses or Time to Adjudicated Events – Randomized Treated Subjects

Endpoint ^a	Number of Subjects with Events		Hazard Ratio [ETV:Non-ETV] (CI) ^b	P-value ^c
	ETV N=6,216	Non-ETV N=6,162		
Primary endpoints				
Overall malignant neoplasm	331	337	0.93 (0.800, 1.084)	0.3553
Liver-related HBV disease progression	350	375	0.89 (0.769, 1.030)	0.1182
Death	238	264	0.85 (0.713, 1.012)	0.0676
Secondary endpoints				
Non-HCC malignant neoplasm	95	81	1.10 (0.817, 1.478)	
HCC	240 ^d	263	0.87 (0.727, 1.032)	
Liver-related death	46	48	0.91 (0.608, 1.365)	

- a Overall malignant neoplasm is a composite event of HCC or non-HCC malignant neoplasm. Liver-related HBV disease progression is a composite event of liver-related death, HCC, or non-HCC HBV disease progression
- b 95.03% CI for overall malignant neoplasm, death, and liver-related HBV disease progression; 95% CI for non- HCC malignant neoplasm, HCC, liver-related death, and non-HCC HBV disease progression.
- c P-values are provided to the COEs that are primary endpoints per protocol specification.

^dsds

CI = confidence interval; N = total number of subjects.

Special populations

Patients with decompensated liver disease

Study AI463048 was a randomized, open-label study of entecavir versus adefovir dipivoxil in 191 (of 195 randomised) patients with HBeAg-positive or –negative chronic HBV infection and evidence of hepatic decompensation, defined as Child-Turcotte-Pugh (CTP) score of 7 or higher. Patients were either HBV-treatment naïve or pretreated (excluding pretreatment with entecavir, adefovir dipivoxil, or tenofovir disoproxil fumarate). At baseline, patients had a mean serum HBV DNA by PCR of 7.83 log₁₀ copies/mL and mean ALT level of 100 U/L; 54% of patients were HBeAg-positive; 35% had genotypic evidence of lamivudine resistance. The baseline mean CTP score was 8.6. The dose of entecavir in this study was 1 mg once daily. Entecavir was superior to adefovir dipivoxil on the primary efficacy endpoint of mean change from baseline in serum HBV DNA by PCR at Week 24. Results for selected study endpoints at Weeks 24 and 48 are shown in Table 14.

Table 14: Selected Endpoints at Weeks 24 and 48, Patients with Decompensated Liver Disease, Study AI463048.

	Week 24		Week 48	
	Entecavir 1 mg (n=100)	Adefovir Dipivoxil 10 mg (n=91)	Entecavir 1 mg (n=100)	Adefovir Dipivoxil 10 mg (n=91)
HBV DNA ^a				
Proportion undetectable (<300 copies/mL)	49%*	16%	57%*	20%
Mean change from baseline (log ₁₀ copies/mL)	-4.48*	-3.40	-4.66	-3.90
Stable or improved CTP score ^b	66%	71%	61%	67%
Model for End-Stage Liver Disease (MELD) score Mean change from baseline ^c	-2.0	-0.9	-2.6	-1.7
HBsAg loss	1%	0	5%	0
Normalisation of: ^d				
ALT (≤1 X ULN)	46/78 (59%)*	28/71 (39%)	49/78 (63%)*	33/71 (46%)
Albumin (≥1 X LLN)	20/82 (24%)	14/69 (20%)	32/82 (39%)	20/69 (29%)
Bilirubin (≤1 X ULN)	12/75 (16%)	10/65 (15%)	15/75 (20%)	18/65 (28%)
Prothrombin time (≤1 X ULN)	9/95 (9%)	6/82 (7%)	8/95 (8%)	7/82 (9%)

^a Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).

^b Defined as decrease or no change from baseline in CTP score

^c Baseline mean MELD score was 17.1 for ETV and 15.3 for adefovir dipivoxil.

^d Denominator is patients with abnormal values at baseline

* p<0.05

ULN = upper limit of normal, LLN = lower limit of normal

HIV/HBV co-infected patients

Study AI463038 was a randomized, double-blind, placebo-controlled study of entecavir versus placebo in 68 patients co-infected with HIV and HBV who were lamivudine refractory (experienced recurrence of HBV viremia while receiving a lamivudine-containing HAART [highly active antiretroviral therapy] regimen). Patients continued their lamivudine-containing HAART regimen (lamivudine dose 300 mg/day) and were assigned to add either entecavir 1 mg once daily (51 patients) or placebo (17 patients) for 24 weeks followed by an open-label phase for an additional 24 weeks where all patients received entecavir. At baseline, patients had a mean serum HBV DNA level by PCR of 9.13 log₁₀ copies/mL. Most patients were HBeAg- positive at baseline, with a mean baseline ALT level of 71.5 U/L. Biochemical and virologic endpoints at Week 24 are shown in Table 15.

Table 15: Biochemical and Virologic Endpoints at Week 24, Study AI463038

	Entecavir 1 mg^a n=51	Placebo^a n=17	Difference Entecavir - Placebo (95% CI)
HBV DNA (by PCR assay ^b)			
Proportion undetectable (≤300 copies/mL)	6%	0	5.9% (-0.6, 12.3)
Mean change from baseline (log ₁₀ copies/mL)	-3.65	+0.11	-3.75 ^c (-4.47,-3.04)
ALT normalization (≤1 x ULN) ^d	34%	8%	26.0 ^e (3.8, 48.1)

^a All patients also received a lamivudine-containing HAART regimen.

^b Roche COBAS Amplicor PCR assay.

^c p<0.0001.

^d n=35 for entecavir and n=12 for placebo.

^e p=0.08

At the end of the open-label phase (Week 48), the mean change from baseline HBV DNA by PCR for patients originally assigned to entecavir was -4.20 log₁₀ copies/mL; 8% of patients had HBV DNA <300 copies/mL by PCR; and 37% of patients with abnormal ALT at baseline had ALT normalization (≤1 times ULN). Entecavir has not been evaluated in HIV/HBV co-infected patients who are not concurrently receiving effective HIV treatment (see section 4.4).

Liver Transplant Recipients

The safety and efficacy of entecavir 1 mg once daily were assessed in a single-arm, open label study in 65 patients who received a liver transplant for complications of chronic HBV infection and had HBV DNA <172 IU/mL (approximately 1000 copies/mL) at the time of transplant. The study population was 82% male, 39% Caucasian, and 37% Asian, with a mean age of 49 years; 89% of patients had HBeAg-negative disease at the time of transplant. Of the 61 patients who were evaluable for efficacy (received entecavir for at least 1 month), 60 also received hepatitis B immune globulin as part of the post-transplant prophylaxis regimen. At Week 72 post-transplant, none of the evaluable patients had HBV recurrence [defined as HBV DNA ≥50 IU/mL (approximately 300 copies/mL)] by last-observation-carried forward analysis. The frequency and nature of adverse events in this study were consistent with those expected in patients who have received a liver transplant and the known safety profile of entecavir.

5.2 Pharmacokinetic properties

Absorption

In healthy subjects, entecavir was rapidly absorbed with peak plasma concentrations occurring between 0.5 and 1.5 hours. There was a dose-proportionate increase in peak plasma concentration (C_{max}) and area under the concentration-time curve (AUC) values following multiple doses ranging from 0.1 to 1 mg. Steady-state was achieved after 6-10 days of once-daily dosing with approximately

2-fold accumulation. C_{max} and trough plasma concentration (C_{trough}) at steady-state were 4.2 and 0.3 ng/mL, respectively, for a 0.5-mg dose, and 8.2 and 0.5 ng/mL, respectively, for a 1-mg dose. In healthy participants, the bioavailability of the tablet was 100% relative to the oral solution.

Oral administration of entecavir 0.5 mg with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal (379 kcal, 8.2 g fat) resulted in a minimal delay in absorption (1-1.5 hour fed vs. 0.75 hour fasted), a decrease in C_{max} of 44-46%, and a decrease in AUC of 18-20%. Therefore, entecavir should be administered on an empty stomach (at least 2 hours before a meal and at least 2 hours after a meal (see section 4.2).

Distribution

The estimated volume of distribution for entecavir was in excess of total body water, suggesting that it has good penetration into tissues. Protein binding to human serum protein *in vitro* was approximately 13%.

Metabolism

Entecavir is not a substrate, inhibitor, or inducer of the CYP450 enzyme system. At concentrations approximately 10,000-fold higher than those obtained in humans, entecavir inhibited none of the major human CYP450 enzymes 1A2, 2C9, 2C19, 2D6, 3A4, 2B6, and 2E1. At concentrations approximately 340-fold higher than those observed in humans, entecavir did not induce the human CYP450 enzymes 1A2, 2C9, 2C19, 3A4, 3A5, and 2B6. Following administration of ^{14}C -entecavir in humans and rats, no oxidative or acetylated metabolites and minor amounts of the phase II metabolites glucuronide and sulfate conjugates were observed.

Elimination

After reaching peak levels, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128-149 hours. The observed drug accumulation index is approximately 2-fold with once-daily dosing, suggesting an effective accumulation half-life of about 24 hours.

Entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady-state ranging from 62% to 73% of the dose. Renal clearance is independent of dose and ranges between 360 and 471 mL/min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion.

Special Populations

Gender/race

The pharmacokinetic profile of entecavir does not vary by gender or race.

Elderly

The pharmacokinetic profile of entecavir does not vary by age.

Renal impairment

The pharmacokinetics of entecavir following a single 1-mg dose were studied in patients (without chronic hepatitis B infection) with selected degrees of renal impairment, including patients whose renal impairment was managed by hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Results are shown in Table 16.

Table 16: Pharmacokinetic Parameters in Subjects with Selected Degrees of Renal Function

	Renal Function Group					
	Baseline Creatinine Clearance (mL/min)					
	Unimpaired >80 (n=6)	Mild >50 ≤80 (n=6)	Moderate 30-50 (n=6)	Severe <30 (n=6)	Severe managed with haemodialysis (n=6)	Severe managed with CAPD (n=4)
C _{max} (ng/mL) (CV%)	8.1 (30.7)	10.4 (37.2)	10.5 (22.7)	15.3 (33.8)	15.4 (56.4)	16.6 (29.7)
AUC _(0-T) (ng•hr/mL) (CV)	27.9 (25.6)	51.5 (22.8)	69.5 (22.7)	145.7 (31.5)	233.9 (28.4)	221.8 (11.6)
CLR (mL/min) (SD)	383.2 (101.8)	197.9 (78.1)	135.6 (31.6)	40.3 (10.1)	N/A	N/A
CLT/F (mL/min) (SD)	588.1 (153.7)	309.2 (62.6)	226.3 (60.1)	100.6 (29.1)	50.6 (16.5)	35.7 (19.6)

CLR=renal clearance; CLT/F=apparent oral clearance.

Dosage adjustment is recommended for patients with a creatinine clearance <50 mL/min, including patients on hemodialysis or CAPD (see section 4.2).

Following a single 1-mg dose of entecavir, hemodialysis removed approximately 13% of the entecavir dose over 4 hours and CAPD removed approximately 0.3% of the dose over 7 days. Entecavir should be administered after hemodialysis.

Hepatic impairment

The pharmacokinetics of entecavir following a single 1-mg dose were studied in patients (without chronic hepatitis B infection) with moderate and severe hepatic impairment. The pharmacokinetics of entecavir were similar between hepatically impaired patients and healthy control subjects; therefore, no dosage adjustment of entecavir is recommended for patients with hepatic impairment.

Post-liver transplant

Entecavir exposure in HBV-infected liver transplant recipients on a stable dose of cyclosporine A or tacrolimus (n=9) was approximately 2-fold the exposure in healthy subjects with normal renal function. Altered renal function contributed to the increase in entecavir exposure in these patients. Before and during entecavir therapy in liver transplant recipients receiving cyclosporine or tacrolimus, renal function should be carefully evaluated (see section 4.2).

Paediatrics

Pharmacokinetic studies have not been conducted in children.

Drug interactions (see section 4.5)

Entecavir is not a substrate, inhibitor, or inducer of the CYP450 enzyme system (see section 5.2). The pharmacokinetics of entecavir are unlikely to be affected by co-administration with agents that are either metabolized by, inhibit, or induce the CYP450 system. Likewise, the pharmacokinetics of known CYP substrates are unlikely to be affected by co-administration of entecavir.

The steady-state pharmacokinetics of entecavir and co-administered drug were not altered in interaction studies of entecavir with each of the following:

- lamivudine,
- adefovir dipivoxil,
- tenofovir disoproxil fumarate.

A pilot study in nine HBV-infected liver transplant recipients suggested that concurrent cyclosporine A (n=5) or tacrolimus (n=4) therapy did not affect the pharmacokinetics of entecavir (see section 5.1). The effect of entecavir on the pharmacokinetics of cyclosporine A or tacrolimus is unknown.

5.3 Preclinical safety data

Genotoxicity

Entecavir was not genotoxic in in vitro assays for bacterial gene mutation, cell transformation and DNA repair, or in an in vivo micronucleus assay for clastogenicity. High concentrations were clastogenic in vitro in human lymphocyte (>10 µg/mL) and mouse L5178Y+/- lymphoma cell (>28 µg/mL) assays, with evidence that the L5178Y+/- cell response was related to perturbation of cellular deoxyribonucleotide triphosphate pools.

Genotoxicity

Two year carcinogenicity studies with entecavir were conducted in mice and rats. In mice, entecavir was administered orally at 4 dosage levels representing exposure multiples of 1, 2.4, 10 and 34 times human exposure at the 1mg dose. The doses in rats achieved exposure multiples relative to the human 1mg dose of <0.3, 0.3, 3.9 and 29 times and 0.3, 0.6, 3.6 and 20 times in males and females, respectively. Increases in the incidence of lung tumours were observed in male and female mice at exposures ≥2.4 times that in humans. Mechanistic studies suggest the lung tumours are likely to be species-specific to mice and probably not relevant to humans. In male rats, entecavir caused pancreatic acinar cell hyperplasia and adenomas at ≥3.9 times human exposure. An increase in skin fibromas was seen in female rats at ≥3.6 times the exposure in humans at 1 mg/day. The incidence of microglial tumours was increased in rats at and above 0.3 times the exposures in humans at 1 mg/day, reaching statistical significance at 20 times human exposure. Other tumours, which were observed only at exposures ≥20 times the exposure in humans at 1 mg/day, included hepatocellular adenomas and/or carcinomas (mice, rats), vascular tumours (mice, rats) salivary duct adenoacanthomas (mice), kidney oncocyoma and malignant mesenchymal tumours (rats), and Zymbal's gland carcinomas (rats; no human counterpart). With the exception of the mouse lung tumours, disruption of cellular deoxyribonucleotide triphosphated (dNTP) pools is likely a significant factor in the carcinogenicity of entecavir, which involves a threshold mechanism. These tumours were generally late appearing and required long term exposure. Based on animal data, an increased risk of cancer in humans treated with entecavir for an extended period cannot be excluded (see section 5.1).

Effects on fertility

Male and female rat fertility was unaffected by drug exposures (AUC) up to approximately 160 (male) and 230 (female) times that in humans treated with a daily dose of 1 mg. Testicular seminiferous tubule degeneration or germinal epithelial maturation arrest was observed in long-term rodent studies, at drug exposures that were ≥10 (mice) and 29 (rats) times the human value, and in dog studies at exposures >379 times the human value. No testicular changes were evident in monkeys at exposures up to 114 times the clinical exposure.

6. Pharmaceutical Particulars

6.1 List of excipients

Entecavir Mylan film coated tablets also contain

Tablet core:

- microcrystalline cellulose
- crospovidone
- lactose monohydrate
- magnesium stearate.

Contains sugars as lactose.

Film coat:

- titanium dioxide
- hydroxypropyl methylcellulose 2910/hypromellose 3cp
- hydroxypropyl methyl cellulose 2910/hypromellose 5cp
- macrogol/polyethylene glycol 400
- polysorbate 80.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Store at or below 25°C.

6.5 Nature and contents of container

White HDPE bottle with a white PP screw cap. Pack size of 30 film-coated tablets.

Cold form blister pack (OPA/Al/PVC) coated with VMCH hot seal lacquer, stored in an outer cardboard carton. Pack size of 30 film-coated tablets.

Not all pack types may be marketed.

6.6 Special precautions for disposal

Not applicable.

7. Medicines Schedule

Prescription Medicine

8. Sponsor Details

Viatris Ltd
PO Box 11-183
Ellerslie
AUCKLAND
www.viatris.co.nz
Telephone 0800 168 169

9. Date of First Approval

20 June 2018

10. Date of Revision of the Text

11 November 2022

Summary table of changes

Section	Summary of new information
2	Included statement "Excipient(s) with known effect".
4.4	Additional information on liver transplant recipients.
4.6	Minor editorial changes
4.7	Added common side effects which may impair ability to drive or operate machineries.
4.8	Tables 5 & 6 added.
5.1, 5.2 & 5.3	Full update to align with source document.
6.1	Listed excipients on separate lines. Removed proprietary name for the film coating. Removed gluten and sugar free statement.
8	Updated sponsor details.